We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A dose of reality for rational therapies.
- Abstract
The article states that many of the biotechnology's greatest therapeutic successes are drugs used as adjuncts to conventional cancer therapies. Interferon was for many years the therapy of choice for use with traditional chemotherapy in certain leukemias and multiple myeloma. Now, molecularly targeted biotech drugs--monoclonal antibodies and small molecules that inhibit protein kinases activated by mutations and chromosomal rearrangements occurring in tumors--have investors and analysts purring about their potential as cancer therapies. The author notes that the approvals of monoclonal antibodies Herceptin and Erbitux and of the small molecule Tarceva are further fueling the enthusiasm.
- Subjects
THERAPEUTICS; BIOTECHNOLOGY research; DRUG therapy; CANCER treatment; ANTINEOPLASTIC agents; MOLECULAR cloning; MONOCLONAL antibodies
- Publication
Nature Biotechnology, 2005, Vol 23, Issue 3, p267
- ISSN
1087-0156
- Publication type
Editorial
- DOI
10.1038/nbt0305-267